- Home
- HRL vs RPRX Comparison
HRL vs RPRX Comparison
Compare HRL & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRL
- RPRX
- Stock Information
- Founded
- HRL 1891
- RPRX 1996
- Country
- HRL United States
- RPRX United States
- Employees
- HRL N/A
- RPRX N/A
- Industry
- HRL Meat/Poultry/Fish
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- HRL Consumer Staples
- RPRX Health Care
- Exchange
- HRL Nasdaq
- RPRX Nasdaq
- Market Cap
- HRL 15.7B
- RPRX 14.2B
- IPO Year
- HRL N/A
- RPRX 2020
- Fundamental
- Price
- HRL $30.58
- RPRX $32.60
- Analyst Decision
- HRL Buy
- RPRX Strong Buy
- Analyst Count
- HRL 4
- RPRX 4
- Target Price
- HRL $33.50
- RPRX $42.50
- AVG Volume (30 Days)
- HRL 3.6M
- RPRX 5.5M
- Earning Date
- HRL 05-29-2025
- RPRX 05-08-2025
- Dividend Yield
- HRL 3.79%
- RPRX 2.71%
- EPS Growth
- HRL N/A
- RPRX N/A
- EPS
- HRL 1.38
- RPRX 1.91
- Revenue
- HRL $11,912,699,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- HRL $2.68
- RPRX $31.56
- Revenue Next Year
- HRL $2.25
- RPRX $5.94
- P/E Ratio
- HRL $22.17
- RPRX $17.05
- Revenue Growth
- HRL N/A
- RPRX N/A
- 52 Week Low
- HRL $27.59
- RPRX $24.05
- 52 Week High
- HRL $36.86
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- HRL 54.84
- RPRX 54.58
- Support Level
- HRL $30.07
- RPRX $32.02
- Resistance Level
- HRL $30.97
- RPRX $32.31
- Average True Range (ATR)
- HRL 0.90
- RPRX 0.97
- MACD
- HRL -0.00
- RPRX 0.12
- Stochastic Oscillator
- HRL 54.71
- RPRX 97.84
About HRL Hormel Foods Corporation
Historically meat-focused, Hormel Foods broadened its lineup to include other protein offerings and become a branded food company. The firm sells its wares through multiple channels, including US retail (62% of fiscal 2024 sales), US food service (32%), and international (6%). By product, 72% of fiscal 2024 sales were from perishable food and 28% from shelf-stable. Major brands include Hormel, Spam, Jennie-O, Columbus, Applegate, Planters, and Skippy. Many of these hold the number one or two market share in their respective categories.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.